| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Lixte Biotechnology Holdings, Inc.$7.21
-0.46 (-6%)
F 16Pipeline Score Richly Valued Biotech · Clinical
Market Cap
72.81 M
EPS
-1.12
P/E Ratio
-
Value Trade
1.66 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
333.38 K
Operating CF
-1.83 M
Total Assets
10.87 M
Total Liabilities
1.69 M
Equity
7.95 M
D/E Ratio
12,345
8.09 %
Week
65.87 %
1 Month
86.67 %
3 Month
31.84 %
6 Month
-78.92 %
5 Year
-90.3 %
All Time
Cash Data
Cash Position
3.25 M
Monthly Burn
610.00 K
Runway
3.4 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
615.06 K
52 Week Range
0.64 - 6.26
% held by Insiders
16.05 %
% held by Institutions
3.81 %
Enterprise Value
71.85 M
Total Shares
11.62 M
Short %
2.25 %
Float Shares
11.61 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lixte Biotechnology Holdings, Inc.
178Total events
2Upcoming
23Tier-1 (high impact)
2014 – 2026Coverage
Upcoming catalysts 2
TBD
T1Partnership / License
Subscribe to view catalyst details
TBD
T2Oral Presentation
Subscribe to view catalyst details
Event history 2
TBD
◆AcquisitionCorporate
Subscribe to view catalyst details
TBD
◆Management ChangeCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | LB-100 | Phase 1b/2 Data readout | Phase 1B/2 | — | – | – | – |
2026-06-30 | LB-100 | Phase 1b/2 Data readout | Phase 1B/2 | — | – | – | – |
2026-06-30 | LB-100 | Phase 1b/2 Data readout | Phase 1B/2 | — | – | – | – |
Drug Pipeline Intelligence
F16
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 13%
Micro Cap (rank 794 of 912)
Percentile RankLixte Biotechnology Holdings, Inc. has significant pipeline risk (16/100), with $47M risk-adjusted pipeline value, led by LB-100 in Tumors (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LB-100 Small molecule | Myelodysplastic Syndromes | Phase 1 | NCT03886662 | 5% | $47M | RECRUITING | 47 | STALLED | F (17) | Jul 1, 2021 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
LB-100 | Ovarian Cancer | — | 2026-04-13 | OS probability 6 months: 0.84 (95%CI 0.64-0.94); OS probability 12 months: 0.69 (95% CI 0.44-0.84); Disease Control Rate: 40% (8/20, 95% CI 19.1-63.9%) Read More | Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference Read More | |
LB-100 | Ovarian Cancer | — | 2026-04-13 | OS probability 6 months: 0.84 (95%CI 0.64-0.94); OS probability 12 months: 0.69 (95% CI 0.44-0.84); Disease Control Rate: 40% (8/20, 95% CI 19.1-63.9%) Read More | Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference Read More | |
LB-100 | Ovarian Cancer | — | 2026-04-13 | OS probability 6 months: 0.84 (95%CI 0.64-0.94); OS probability 12 months: 0.69 (95% CI 0.44-0.84); Disease Control Rate: 40% (8/20, 95% CI 19.1-63.9%) Read More | Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LIXT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LIXT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How LIXT ranks across every disease it competes inCompetitive Position is a premium feature
See how LIXT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial